Table 1 Summary of basic characteristics
Authors | Year | Country | Hypertension status | Antihypertensive treatment at baseline | Trial name (ID) | Age | Men | N of interventiona | N of controla |
|---|---|---|---|---|---|---|---|---|---|
Vetter et al. [11] | 2000 | Switzerland | Hypertension | With monotherapy of losartan | SVATCH Study | 57.9 | 49.2% | 296 | 326 |
Mehos et al. [12] | 2000 | USA | Hypertension | With antihypertensive medication | – | 58.8 | 30.6% | 18 | 18 |
Rogers et al. [13] | 2001 | USA | Hypertension | With or without antihypertensive treatment | – | 61.4 | 49.6% | 60 | 61 |
Broege et al. [14] | 2001 | USA | Hypertension | BP > 150/90 mmHg without antihypertensive treatment, age ≥ 65 (the treated group was not considered due to inappropriate protocol) | – | 73 | 32.5% | 9 | 10 |
Rudd et al. [15] | 2004 | USA | Hypertension | BP ≥ 150/95 mmHg, with or without antihypertensive treatment | – | 59.5 | 47.0% | 74 | 76 |
Halme et al. [16] | 2005 | Finland | Hypertension | With or without antihypertensive treatment | HOMER - | 57.2 | 32.8% | 113 | 119 |
Zillich et al. [17] | 2005 | USA | Hypertension | With antihypertensive treatment | HOME - | 65.0 | 39.2% | 64 | 61 |
Marquez-Contreras et al. [18] | 2006 | Spain | Hypertension | With or without antihypertensive treatment | EAPACUM–HTA | 59.1 | 51.0% | 100 | 100 |
Verberk et al. [19] | 2007 | Netherlands | Hypertension | With or without antihypertensive treatment | HOMERUS | 55 | 55% | 214 | 216 |
Kauric-Klein and Artinian [20] | 2007 | USA | Hypertension | With or without antihypertensive treatment, hemodialysis | – | 48.7 | 32% | 17 | 17 |
Artinian et al. [21] | 2007 | USA | Hypertension | With or without antihypertensive treatment | – | 59.6 | 36% | 194 | 193 |
Tobe et al. [22] | 2008 | Canada | Hypertension | With antihypertensive treatment | IMPPACT | 62.9 | 49% | 173 | 97 |
Madsen et al. [23] | 2008 | Denmark | Hypertension | With or without antihypertensive treatment | (NCT00282334) | 55.9 | 50% | 113 | 123 |
Green et al. [24] | 2008 | USA | Hypertension | With antihypertensive treatment | e-BP (NCT00158639) | 59.1 | 48% | (1) 259 (2) 261 | 258 |
Parati et al. [25] | 2009 | Italy | Hypertension | With or without antihypertensive treatment | TeleBPCare - | 57.5 | 54% | 187 | 111 |
da Silva et al. [26] | 2009 | Brazil | Hypertension | With or without antihypertensive treatment, hemodialysis | ([CRG060800146]) | 51.6 | 66.2% | 34 | 31 |
Dejesus et al. [27] | 2009 | USA | Hypertension | Type 2 diabetes (antihypertensive treatment status is uncertain) | – | >60, 76% | 48% | 19 | 17 |
Bosworth et al. [28] | 2009 | USA | Hypertension | With or without antihypertensive treatment | TCYB (NCT00123058) | 61 | 34% | 158 | 159 |
Rinfret et al. [29] | 2009 | Canada | Hypertension | With or without antihypertensive treatment | (NCT00374829; ISRCTN75436659) | 56 | 54% | 111 | 112 |
Godwin et al. [30] | 2010 | Canada | Hypertension | With antihypertensive medications and not at target BP | – | 68 | 49% | 285 | 267 |
McManus et al. [31] | 2010 | UK | Hypertension | With antihypertensive treatment | TASMINH2 (ISRCTN17585681) | 66 | 47% | 234 | 246 |
Varis and Kantola [32] | 2010 | Finland | Hypertension | Without antihypertensive treatment | – | N/A | 39% | 104 | 85 |
Bosworth et al. [33] | 2011 | USA | Hypertension | With antihypertensive treatment | HINTS (NCT00237692) | 64 | 16% | 149 | 147 |
Magid et al. [34] | 2011 | USA | Hypertension | With antihypertensive treatment | (NCT00520988) | 65.9 | 65% | 138 | 145 |
Hebert et al. [35] | 2012 | USA | Hypertension | with antihypertensive treatment self-described black or Hispanic adults | – | 61 | 34% | (1)120 (2)120 | (1)129 (2)118 |
Fuchs et al. [36] | 2012 | Brazil | Hypertension | With antihypertensive treatment | MONITOR (NCT00921791) | 59 | 40% | 62 | 59 |
Piette et al. [37] | 2012 | USA and Mexico | Hypertension | With or without antihypertensive treatment | (NCT01484782) | 57.6 | 33% | 89 | 92 |
Williams et al. [38] | 2012 | Australia | Hypertension | With antihypertensive treatment, diabetes, and chronic kidney disease | MESMI (ACTRN12607000044426) | 67.0 | 56% | 39 | 41 |
Kerry et al. [39] | 2013 | UK | Hypertension | With or without antihypertensive treatment, Stroke or transient ischemic attack within the 9 months before enrollment and hypertension. | (NCT00514800) | 72 | 57% | 187 | 194 |
Magid et al. [40] | 2013 | USA | Hypertension | With or without antihypertensive treatment | (NCT01162759) | 60 | 60% | 175 | 173 |
McKinstry et al. [41] | 2013 | UK | Hypertension | With or without antihypertensive treatment | HITS (ISRCTN72614272) | 61 | 59% | 218 | 225 |
Margolis et al. [42] | 2013 | USA | Hypertension | With or without antihypertensive treatment | (NCT00781365) | 61.1 | 55% | 228 | 222 |
Ogedegbe et al. [43] | 2014 | USA | Hypertension | With antihypertensive treatment | CAATCH (NCT00233220) | 56.5 | 28% | 529 | 510 |
Stewart et al. [44] | 2014 | Australia | Hypertension | With antihypertensive treatment (at least one hypertensive medication) | HAPPy - | 66.7 | 51% | 207 | 188 |
McManus et al. [45] | 2014 | UK | Hypertension | With high-risk conditions (cardiovascular disease, diabetes, stage 3 chronic kidney disease, or coronary heart disease) | TASMIN-SR - | 69.5 | 60% | 276 | 276 |
Hosseininasab et al. [46] | 2014 | Iran | Hypertension | With or without antihypertensive treatment | (NCT01525108) | 58.7 | 38.7% | 97 | 97 |
Kim et al. [47] | 2014 | USA | Hypertension | With or without antihypertensive treatment (Korean American aged ≥60 years) | Self-Help Intervention Program on the Control of home BP (NCT00406614) | 70.9 | 30% | 184 | 185 |
Yi et al. [48] | 2015 | USA | Hypertension | With antihypertensive treatment | (NCT01123577) | 61.3 | 32% | 409 | 419 |
Hanley et al. [49] | 2015 | UK | Hypertension | With antihypertensive treatment (Stroke/TIA survivors with uncontrolled BP) | (ISRCTN61528726) | 70.9 | 60% | 40 | 15 |
Aekplakorn et al. [50] | 2016 | Thailand | Hypertension | With antihypertensive treatment | – | 59.4 | 35% | 111 | 113 |
Kim et al. [51] | 2016 | USA | Hypertension | With antihypertensive treatment | (NCT01975428) | 57.6 | 32% | 52 | 43 |
Tzourio et al. [52] | 2017 | France | Hypertension | With or without antihypertensive treatment, age ≥ 65 | (ISRCTN97164929) | 79.1 | 43.0 | 526 | 517 |
Klarskov et al. [53] | 2018 | Denmark | Hypertension | With or without antihypertensive treatment | BRIDGE | 61.8 | 48.1% | 533 | 515 |
Martinez et al. [54] | 2018 | Spain | Hypertension | With antihypertensive treatment | RECAVA | 66 | 64% | 64 | 52 |
McManus et al. [55] | 2018 | UK | Hypertension | With antihypertensive treatment | TASMINH4 | 66.9 | 53.6% | (1) 391 (2) 389 | 393 |
Pan et al. [56] | 2018 | China | Hypertension | With or without antihypertensive treatment | – | 57.2 | 46.8% | 52 | 55 |
Skolarus et al. [57] | 2018 | USA | Hypertension | With or without antihypertensive treatment | Reach Out ED (NCT02664610) | 58 | 21% | 48 | 46 |
Cuffee et al. [58] | 2019 | USA | Hypertension | With antihypertensive treatment | ([NCT01035554]) | 58.7 | 59.2% | 106 | 107 |
Gu et al. [59] | 2020 | China | Hypertension | With antihypertensive treatment, diabetes, aged ≥ 60 | (UMIN000021613) | 71.1 | 36.7% | 45 | 45 |
Ojji et al. [60] | 2020 | Nigeria | Hypertension | With or without antihypertensive treatment | – | 44 | 40% | 20 | 20 |
Zha et al. [61] | 2020 | USA | Hypertension | With antihypertensive treatment | (NCT02632838) | 52.3 | 12% | 12 | 13 |
Ionov et al. [62] | 2021 | Russia | Hypertension | With antihypertensive treatment | – | 47 | 60% | 160 | 80 |
McManus et al. [63] | 2021 | UK | Hypertension | With antihypertensive treatment | HOME BP (ISRCTN13790648) | 66 | 54% | 305 | 317 |
Zhang et al. [64] | 2021 | China | Hypertension | With or without antihypertensive treatment | (NCT00670566) | 55.1 | 47% | 96 | 405 |
Akl et al. [65] | 2021 | Lebanon | Hypertension | With antihypertensive treatment (uncertain if the study included patients without antihypertensive treatment) | (ISRCTN16450193) | 60.2 | 51% | 39 | 40 |
Margolis et al. [66] | 2022 | USA | Hypertension | With or without antihypertensive treatment | Hyperlink 3 (NCT02996565) | 60.2 | 47% | 1648 | 1423 |
Okoro et al. [67] | 2022 | Nigeria | No restriction | CKD Stage1-4 with antihypertensive treatment | – | 52.2 | 38% | 73 | 74 |
Muijsers et al. [68] | 2022 | Netherlands and Germany | No restriction | Women with a history of preeclampsia and/or HELLP syndrome but without antihypertensive treatment | BP-PRESELF (NCT03228082) | 45.4 | 0% | 96 | 95 |
Calderón-Anyosa et al. [69] | 2023 | Peru | Hypertension | With antihypertensive treatment | (NCT03524456) | 68.1 | 32% | 20 | 20 |
Doogue et al. [70] | 2023 | UK | Hypertension | Stroke or TIA patients with antihypertensive treatment | TASMIN5S IRL (ISRCTN57946500) | 70 | 80% | 10 | 5 |
Hoppe et al. [71] | 2023 | USA | Hypertension | With antihypertensive treatment, age of 18–39 years | the MyHEART randomized clinical trial (NCT03158051) | 35 | 53% | 157 | 159 |
Leupold et al. [72] | 2023 | Germany | Hypertension | With antihypertensive treatment | PIA (DRKS00012680) | 58 | 53% | 331 | 305 |
Martínez-Ibáñez et al. [73] | 2023 | Spain | Hypertension | With antihypertensive treatment | ADAMPA (NCT03242785) | 64.4 | 47% | 156 | 156 |
Nejamis et al. [74] | 2023 | Argentina | Hypertension | With or without antihypertensive treatment | – | 58.6 | 49% | 144 | 148 |
Ramos-Zavala et al. [75] | 2023 | México | Hypertension | With antihypertensive treatment | – | 58.1 | 45.5% | 94 | 84 |
